A Phase 3, Multicenter, Randomized Study To Evaluate The Substitution of Marqibo (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincistrine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects > or = 60 Years old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Trial Profile

A Phase 3, Multicenter, Randomized Study To Evaluate The Substitution of Marqibo (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincistrine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects > or = 60 Years old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Vincristine (Primary) ; Antineoplastics
  • Indications Acute lymphoblastic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms HALLMARQ
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 08 Dec 2015 Results(n=26) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 26 Apr 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 16 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top